Temozolomide

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12585 publications

Retraction Note: UBE2D3 regulated by WTAP-mediated m6A modification inhibits temozolomide chemosensitivity in glioblastoma.

Retraction Note: UBE2D3 regulated by WTAP-mediated m6A modification inhibits temozolomide chemosensitivity in glioblastoma.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: June 23, 2026

Correction: Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.

Correction: Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.

Journal: BJC reports

Published: June 23, 2026

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

Journal: Future oncology (London, England)

Published: June 19, 2026

Long-Term Outcome of Molecularly Defined Oligodendrogliomas: Comparison of Grade 2 and 3 Tumors.

Long-Term Outcome of Molecularly Defined Oligodendrogliomas: Comparison of Grade 2 and 3 Tumors.

Journal: Neurology

Published: June 16, 2026

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal: Journal of chemotherapy (Florence, Italy)

Published: June 13, 2026

Exploring the potential of multiple receptors overexpressed on glioblastoma cells as biomarkers for the targeted therapy; a review.

Exploring the potential of multiple receptors overexpressed on glioblastoma cells as biomarkers for the targeted therapy; a review.

Journal: Therapeutic delivery

Published: June 11, 2026

Right Frontal Isocitrate Dehydrogenase (IDH)-Mutant WHO Grade 3 Oligodendroglioma Presenting With Morning Headache and Gait Imbalance.

Right Frontal Isocitrate Dehydrogenase (IDH)-Mutant WHO Grade 3 Oligodendroglioma Presenting With Morning Headache and Gait Imbalance.

Journal: Cureus

Published: June 10, 2026

Pancreatic Neuroendocrine Tumor in Lynch Syndrome: Expanding the Tumor Spectrum of Mismatch Repair Deficiency.

Pancreatic Neuroendocrine Tumor in Lynch Syndrome: Expanding the Tumor Spectrum of Mismatch Repair Deficiency.

Journal: Cureus

Published: June 06, 2026

Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review

Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: June 03, 2026

Ferulic Acid Increases Temozolomide Sensitivity in Glioblastoma Cells, Causing DNA Damage and Inhibiting Cell Proliferation.

Ferulic Acid Increases Temozolomide Sensitivity in Glioblastoma Cells, Causing DNA Damage and Inhibiting Cell Proliferation.

Journal: Turkish neurosurgery

Published: June 02, 2026

Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature.

Multimodal management of giant prolactinoma with extensive amyloid spherule deposition: a case report with review of the literature.

Journal: Endocrine journal

Published: May 27, 2026

Hyperglycemia promotes O-GlcNAcylation-dependent vulnerability and modulates temozolomide response in glioblastoma.

Hyperglycemia promotes O-GlcNAcylation-dependent vulnerability and modulates temozolomide response in glioblastoma.

Journal: Biochemical and biophysical research communications

Published: May 26, 2026

Showing 1-12 of 12,585

Last Updated: 06/30/2026